Research is a key strength for Biogen Idec. Today, our goal is to enhance and expand our efforts in the therapeutic areas of oncology, neurology, and rheumatology.

Biogen Idec is one of the world’s largest biotechnology companies, with an R&D budget that exceeds $750 million. The company has 750 R&D; employees, including approximately 300 in discovery research. The company’s research is closely integrated with its commercial strengths, with leading-edge research in oncology, immunology and neurobiology. Additional discovery and development efforts are aimed at adding substantial value to Biogen Idec’s existing products by extending their use to other diseases.

Biogen Idec has established two Centers of Excellence for its research effort: one at the corporate headquarters in Cambridge, MA and the other in San Diego, CA in collaboration with a Canadian pharmacy in Bridgeport, CT. This internal capability is supplemented with selective alliances with both other companies and academic research groups aimed at helping Biogen Idec continue to meet the challenges of its future growth.